ABOUT US
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
VIDEOS
FEATURED PRODUCTS
-
MabSelect™ VL resin — protein L resin for affinity capture of antibody Fabs, bispecifics, and other variants containing a kappa light chain.
-
Supplements cell culture with amino acids, vitamins, and glucose and manufactured to meet cGMP manufacturing standards and QC specifications.
-
ÄKTA™ chromatography systems can handle both simple and complex purification tasks and accelerate daily routines. All systems are controlled by UNICORN™ software, a common control platform and user interface for all scales of operation.
-
Cytiva provides filtration solutions and support for integrated bioprocessing applications at every step and every scale of the drug development, validation and manufacturing process.
-
We offer a range of systems, accessories, and reagents for label-free analysis using microcalorimetry or surface plasmon resonance (SPR). These techniques provide information-rich, real time data without the use of labels.
-
Protein A chromatography resin with excellent capacity and alkaline stability for cost-efficient and extremely robust mAb capture.
-
Accelerate your biomanufacturing capacity with purpose-built modules
KUBio™ box modular bioprocessing environments are designed to help biopharmaceutical manufacturers bring high-quality biopharmaceuticals to market more quickly. By reducing typical design and construction times and streamlining process execution, they support future expansion and replication needs. Available KUBio™ box modular environments for biosafety levels 1 and 2 (BSL-1 and BSL-2) can be delivered in 10 to 15 months for implementation inside existing infrastructure. The result? Reduced project risk, accelerated delivery of next-gen therapies, and greater flexibility at different production scales and product technologies.
-
Transform your space to fit your needs
Configurable FlexFactory™ biomanufacturing process trains can help scientists better control the production and processing of different viral vectors and new modalities—all within the same space. Plan your agile manufacturing strategy with greater efficiency and integration to address current and future capacity needs.
-
Single-use, automated filtration system designed to deliver robust process control during the clarification/harvest step.
-
ÄKTA flux is a semi-automated tangential flow filtration/cross flow filtration system for concentration and diafiltration as well as cell harvest and clarification.
BROCHURES AND DATASHEETS
- Advanced Automation System For Flexible Aseptic Filling
- Closed Robotic Isolator For Reduced Risk And Flexibility In Vial Filling
- Centralized Data Aggregation Software
- Bioreactors Designed For Cell Growth And Expansion
- Filtration Hardware
- An Automated Single-Use Filtration System For Crossflow Filtration
- Built-In Knowledge For Planning And Controlling Runs And Analyzing Results
- Preparative Chromatography System For Lab-Scale Protein Purification
- A Flexible And Intuitive Chromatography System
- A Ready-To-Use, Single-Use Liquid Chromatography System
WEBINARS
APPLICATION NOTES
- Balancing Protein A Resin Cost, Performance, And Productivity
- Adapting Single-Use Chromatography To Manufacturing Scale
- Bulk Filling Of Drug Substance | Accurate Aliquoting
- Developing A HIC Polishing Step For The Removal Of mAb Aggregates
- An End-To-End, Semi-Continuous Process For mAb Production
- Quantitating Binding Similarities In IgG Fcγ Receptor Analysis
- Adenovirus Production In Single-Use Bioreactor System
- Downstream Process Development For Efficient Purification Of Adenovirus
- Optimization Of Midstream Cell Lysis And Virus Filtration Steps In An Adenovirus Purification Process
- Obtaining Good Yields With High Purity Of An N-terminal Histidine-Tagged Protein
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
The FDA is rethinking CMC oversight for cell and gene therapies, prioritizing science‑based justification over rigid validation models. Learn how this lifecycle‑focused approach could reduce burden.
-
Explore how adding a traceless tag enables streamlined affinity purification for recombinant proteins, and how this approach compares with a conventional process in development time, recovery, and purity.
-
Clarifying post–virus inactivation streams with a charged depth filter can remove precipitates while significantly reducing HCPs. See how a dual‑layer filtration approach supports stronger impurity control.
-
New technologies and regulatory changes are shaping safer, more efficient filling processes. Discover why innovation is key to protecting patients and advancing therapies.
-
Aseptic filling is vital yet often guided by outdated practices. Discover expert insights on modern technologies, evolving regulations, and data-driven strategies to improve compliance and reduce risk in this critical manufacturing step.
-
Gain insight into how Annex 1 reshapes aseptic process validation, as well as into risk reduction by design and why isolators are redefining modern sterile manufacturing standards.
-
Rapid GMP certification is possible with Annex 1-aligned aseptic workflows that reduce contamination risks. Learn how advanced automation and isolator technologies help CDMOs meet regulatory demands.
-
Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.
-
Single-use technologies are reshaping biomanufacturing workflows. Discover the key stages of implementation and how strategic choices drive success across the entire production process.
-
Biopharma’s future depends on collaboration. Discover how cross-industry partnerships and shared resources can accelerate innovation, overcome talent gaps, and strengthen the global R&D ecosystem.